Systemic antifungal agents;Antifúngicos de uso sistémico

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 7, 2003, Pages 366-380+390

  Lumbreras, Carlos ^a   Lizasoain, Manuel ^a   Aguado, José María ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antifungals; Fungal infection; New drugs

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; DICOUMAROL; FLUCONAZOLE; FLUCYTOSINE; GLIPIZIDE; ISONIAZID; ITRACONAZOLE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TERFENADINE; TOLBUTAMIDE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ALOPECIA; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BRADYCARDIA; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CRYPTOCOCCUS; DIARRHEA; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EDEMA; EOSINOPHILIA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; HYPOTHERMIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PARKINSONISM; PHARMACODYNAMICS; PREVENTIVE MEDICINE; RASH; REVIEW; SACCHAROMYCES; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VISUAL HALLUCINATION; VOMITING;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANTIFUNGAL AGENTS; FLUCYTOSINE; HUMANS; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 0141793090     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050528     Document Type: Review

References (55)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001;32:358-66.
3. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79: 250-60.
4. Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001;33:95-106.
5. Lumbreras C, Vicente C, López-Medrano F. Importancia del tratamiento antifúngico precoz en el tratamiento de la infección fúngica invasora. Enferm Infecc Microbiol Clin 2003;(Supl 2):46-56.
6. Sanglard D. Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 2002;20:462-71.
7. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998;73:1205-25.
8. Adler-Moore J, Proffitt RT. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002;49(Suppl 1):21-30.
9. Arikan S, Rex JH. Lipid-based antifungal agents: current status. Curr Pharm Des 2001;7:393-415.
10. Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000;20:1-23.
11. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-78.
12. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8.
13. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
14. Monforte V, Román A, Gavalda J, Bravo C, Tenorio L, Ferrer A, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 2001;20: 1274-81.
15. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-1.
16. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
17. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63.
18. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17.
19. Terrell CL. Antifungal agents. Part II. The azoles. Mayo Clin Proc 1999;74:78-100.
20. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
21. Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi. Enferm Infecc Microbiol Clin 2002;20:523-9.
22. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30.
23. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000;14:721-39.
24. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9.
25. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21.
26. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326: 845-51.
27. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
28. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
29. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 20031;101:3365-72.
30. Lumbreras C, Cuervas-Mons V, Jara P, Del Palacio A, Turrion VS, Barrios C, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174:583-8.
31. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:729-37.
32. Kaufman D, Boyle R, Hazen KH, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6.
33. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001;32:1191-200.
34. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108:282-9.
35. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents: A review of itraconazole and fluconazole. Pharmacotherapy 1990;10:146-53.
36. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994;97:135-44.
37. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157:1857-62.
38. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33: 83-90.
39. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic Stem-Cell transplant recipients. A Multicenter, Randomized Trial. Ann Intern Med 2003;138:705-13.
40. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002;74:688-95.
41. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135: 412-22.
42. Kontoyiannis DP. A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America. Pharmacotherapy 2001;21:175S-187S.
43. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
44. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54.
45. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998;12:2227-8.
46. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, De la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.
47. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
48. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
49. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffali J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
50. Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother 2003;37:90-8.
51. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study ofcaspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
52. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2001; 33:1529-35.
53. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002;31:183-7.
54. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
55. Maertens J. Caspofungin as salvage therapy of invasive aspergillosis. Resumen M-868. En program and abstracts of the 42th ICAAC Congress. San Diego, 2002.